Clinical pharmacokinetics of fosphenytoin: An overview

Neurologist

Volumn 5, Issue 4, 1998, Pages S23-S29

  Eldon, Michael A ^a   Knapp, Lloyd E ^a   Kugler, Alan R ^a  

^a PFIZER INC   (United States)

Author keywords

Fosphenytoin; Patient demographics; Pharmacokinetics; Phenytoin; Status epilepticus

Indexed keywords

ANTICONVULSIVE AGENT; FOSPHENYTOIN SODIUM;

ANTICONVULSANT THERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; EPILEPSY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW;

EID: 0031733748     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Eldon MA, Loewen GR, Voigtman RE, Koup JR, Holmes GB, Hunt TL, et al. Pharmacokinetics and tolerance of fosphenytoin and phenytoin administered intravenously to healthy subjects [abstract]. Can J Neurol Sci 1993;20(Suppl 4):S180.
2. Knapp LE, Kugler AR, Eldon MA. Fosphenytoin: Pharmacokinetics and administration. Emerg Med 1996;28(Suppl):9-16.
3. Kugler AR, Knapp LE, Eldon MA. Rapid attainment of therapeutic phenytoin concentrations following administration of loading doses of fosphenytoin: A meta-analysis [abstract]. Neurology 1996;46(Suppl): A176.
4. Browne TR, Kugler AR, Eldon MA. Pharmacology and pharmacokinetics of fosphenytoin. Neurology 1996; 46(Suppl 1):S3-7.
5. Eldon MA, Loewen GR, Voigtman PJEÌ, Holmes GB, Hunt TL, Sedman AJ. Safety, tolerance, and pharmacokinetics of intravenous fosphenytoin [abstract], Clin Pharmacol Ther 1993;53:212.
6. Baron B, Hankin S, Knapp L. Incidence of complications with intravenous administration of fosphenytoin (Cerebyx) compared with Dilantin. Neurology 1995;45(Suppl 4):248-9.
7. Leppik IE, Boucher R, Wilder BJ, Murthy VS, Rask CA, Watridge C, et al. Phenytoin prodrug: Preclinical and clinical studies. Epilepsia 1989;30(Suppl 2):S22-6.
8. Leppik IE, Boucher BA, Wilder BJ, Murthy VS, Watridge C, Graves NM, et al. Pharmacokinetics and safety of a phenytoin prodrug given IM or IV in patients. Neurology 1990;40:456-60.
9. Uthman BM, Wilder BJ, Ramsay FIE. Intramuscular use of fosphenytoin: An overview. Neurology 1996;46(Suppl 1):S24-8.
10. Cerebyx (fosphenytoin sodium injection) package insert. Moms Plains: Parke-Davis, 1996.
11. Wilder BJ, Campbell K, Ramsay RE, Garnett WR, Pellock JM, Henkin SA. Safety and tolerance of multiple doses of intramuscular fosphenytoin substituted for oral phenytoin in epilepsy or neurosurgery. Arch Neurol 1996;53:764-8.
12. Fernley HN. Mammalian alkaline phosphatases. In: Boyer PD, editor. The enzymes. New York: Academic Press, 1971:417-43.
13. Varia SA, Stella VJ. Phenytoin prodrugs V: In vivo evaluation of some water-soluble phenytoin prodrugs in dogs. J Pharm Sci 1984; 73:1080-7.
14. Vana SA, Stella VJ. Phenytoin prodrugs VI: In vivo evaluation of a phosphate ester prodrug of phenytoin after parenteral administration to rats. J Pharm Sci 1984;73:1087-90.
15. Eldon MA, Sedman AJ, Kugler AR. Intravenous administration of fosphenytoin: Lack of significant change in fosphenytoin metabolites phosphate and formate, and in electrolyte concentrations [abstract]. Epilepsia 1996;37(Suppl 5): 156.
16. Baumann K, Angerer J. Occupational chronic exposure to organic solvents: VI—Formic acid concentration in blood and urine as an indicator of methanol exposure. Int Arch Occup Environ Health 1979; 42:241-9.
17. Schweda P. Formic acid levels in body fluids as index of formaldehyde exposure. In: Proceedings of the 21st international meeting of the International Association of Forensic Toxicologists. September 1984, Brighton, UK: International Association of Forensic Toxicologists, 309-12.
18. Tozer TN, Winter ME. Phenytoin. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics, principles of therapeutic drug monitoring. Vancouver: Applied Therapeutics, 1992:25-9.
19. Cranford RE, Leppik IE, Patrick B, Anderson CB, Kostick B. Intravenous phenytoin: Clinical and pharmacokinetic aspects. Neurology 1978;28:874-80.
20. Donovan PJ, Cline D. Phenytoin administration by constant intravenous infusion: Selective rates of administration. Ann Emerg Med 1991;20:139-42.
21. Ramsay RE, Philbrook B, Martinez DA, Calleramek J, Gallo BV, Acosta A. A double-blinded, randomized safety comparison of rapidly infused intravenous loading doses of fosphenytoin versus phenytoin [abstract]. Epilepsia 1995;36(Suppl 4):52.
22. Ramsay RE, Philbrook B, Fischer JH, Sloan EP, Allen FH, Runge JW, et al. Safety and pharmacokinetics of fosphenytoin (Cerebyx) compared with Dilantin following rapid intravenous administration [abstract]. Neurology 1996;46(Suppl):A245.
23. Henkin SA, Knapp LE, Smith MF, Baron BA. Tolerance of intravenous fosphenytoin (Cerebyx) compared with Dilantin [abstract]. Neurology 1996;46(Suppl):A245.
24. Kugler AR, Knapp LE, Eldon MA. Intravenous administration of fosphenytoin: Pharmacokinetics and dosing considerations in special populations [abstract]. Epilepsia 1996;37(Suppl 5): 156.
25. Bauer LA, Blouin RA. Age and phenytoin kinetics in adult epileptics. Clin Pharmacol Ther 1982;31:301-4.
26. MacKichean J. Influence of protein binding and use of unbound (free) drug concentrations. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics, principles of therapeutic drug monitoring. Vancouver: Applied Therapeutics, 1992:5-48.